Drug intelligence / Profile preview

Sanjin

Development stage: Unknown
Lead developer: Guilin Sanjin Pharmaceutical
Administration: Oral

Overview

Sanjin is a Traditional Chinese Medicine (TCM) formulation primarily used for the treatment of urinary tract infections (UTIs), including acute simple lower urinary tract infections and chronic prostatitis. Developed and manufactured by Guilin Sanjin Pharmaceutical, the tablets are composed of five medicinal herbs: *Rosa laevigata*, *Smilax china*, *Centella asiatica*, *Lygodium japonicum*, and *Melastoma dodecandrum*. Its mechanism of action involves antibacterial, anti-inflammatory, and diuretic properties, as well as the modulation of the immune response to reduce recurrence rates of infections. It is widely used in China as an alternative or adjunct to antibiotic therapy for urogenital conditions.

Brand names: Sanjin TabletsSanjin Pian
Other names: Sanjin tabletsSanjin-pian

Beyond the preview

Go deeper on Sanjin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sanjin.

Explore the full profile